阿托伐他汀钙对急性脑梗死临床疗效及血清脑源性神经营养因子的影响

摘要

目的 研究阿托伐他汀钙对急性脑梗死患者临床疗效及血清脑源性神经营养因子(BDNF)水平的影响.方法 将50例急性脑梗死患者随机分为治疗组和对照组,对照组给予神经内科常规药物治疗,治疗组在此基础上加用阿托伐他汀钙.采用双抗体夹心酶联免疫吸附法检测两组患者治疗前和治疗6周后血清BDNF水平,并采用美国国立卫生院神经功能缺损量表(NIHSS)评价患者神经功能缺损状况及用日常生活活动能力量表(ADL)评价各组患者活动能力.结果 两组患者治疗后血清BDNF较治疗前均增加(P<0.01),治疗组增加程度明显高于对照组(P<0.01);两组患者治疗后神经功能缺损程度评分较治疗前明显减少(P<0.01),治疗组减少程度高于对照组(P<0.05);日常生活能力均有明显好转(P<0.01),而治疗组日常生活功能改善程度优于对照组(P<0.01).结论 阿托伐他汀钙可促进急性脑梗死患者血清BDNF表达,这可能是其促进神经功能缺损恢复的机制之一.%Objective To assess effecliness of the alorvaslalin calcium in ihe Irealmenl of acule cerebral in-farclion and its influence on the serum levels of brain-derived neurolrophic faclor (BDNF) . Methods The 50 palienls with acule cerebral infarction were randomly divided into trealmenl group ( n = 25) and control group ( n =25) . The control group received routine medication, while the treatment group additionally received atorvastatin calcium. Their serum levels of BDNF were measured by double-antibody sandwich enzyme-linked immunosorbent assay( ELISA) before and after six weeks of the treatment. Their clinical effectiveness was assessed according to National Institutes of Health Stroke Scale( NIHSS) and the Activity of Daily Living Scale( ADL) . Results After the treatment, the serum levels of BDNF in the two groups were higher than those before the treatment, and serum level of BDNF in the treatment group was significantly higher than that in the control group. NIHSS scores of the both groups decreased significantly after the treatment. Atorvastatin caused a signifiant reduction in NIHSS scores and ADL scores in treatment group compaired to the control group. ADL scores in the both groups were significantly improved. Conclusion Atorvastatin calcium could increase the serum levels of BDNF in patients with acute cerebral infarction, which may promote the recovery of neurological deficit.